CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 38 enrolled
Drug / intervention
Atomoxetine +2 moredrug
Likely dose
Atomoxetine 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00360269
NCT00360269Phase 2Completed
CompareCT.gov

Atomoxetine Treatment for ADHD and Marijuana Dependence

Medical University of South Carolina·interventional·Posted Aug 4, 2006·Updated Dec 30, 2014

In Brief

A Phase 2 clinical trial evaluating Atomoxetine, Motivational enhancement therapy, and 1 other intervention for Marijuana Abuse and Attention Deficit Disorder With Hyperactivity. Completed, enrolled 38 participants across 1 site.

Detailed Summary

The aim of the study is to determine if atomoxetine treatment combined with motivational enhancement therapy is effective in reducing marijuana use in adult individuals with attention-deficit hyperactivity disorder and marijuana dependence.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMarijuana Abuse, Attention Deficit Disorder With Hyperactivity
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 4, 2006
Enrollment StartNov 1, 2005
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 19.9 years ago

Interventions

Atomoxetinedrug

25 to 100 mg daily

Motivational enhancement therapyprocedure

Three sessions

Placebodrug

25 to 100 mg daily